Results 291 to 300 of about 229,451 (392)
Androgen receptor as a potential therapeutic target in castration-resistant prostate cancer: a bibliometric analysis (2005-2024). [PDF]
Zhang J, Yuan W, Zhang T, Liu X, Xu D.
europepmc +1 more source
Abstract Background Despite growing concerns about antimicrobial resistance, prophylactic antimicrobials continue to be routinely administered in many procedures, including dental extractions. Further evidence‐based research is needed on whether their use influences post‐operative complication rates.
Marlies Schnierer+4 more
wiley +1 more source
CHD1 loss reprograms SREBP2-driven cholesterol synthesis to fuel androgen-responsive growth and castration resistance in SPOP-mutated prostate tumors. [PDF]
Chen F+20 more
europepmc +1 more source
ABSTRACT Objectives Treatment strategies for metastatic castration‐sensitive prostate cancer (mCSPC) have advanced significantly, yet the prognostic impact of time to castration resistance (TTCR) on overall survival (OS) remains unclear. This retrospective study aimed to evaluate the relationship between TTCR and OS.
Hiroaki Iwamoto+12 more
wiley +1 more source
Molecular Mechanisms of Castration-Resistant Prostate Cancer Progression. [PDF]
Naeem AA, Abdulsamad SA.
europepmc +1 more source
Therapeutic cancer vaccines require CD8+ T‐cell activation for efficacy. This response can be enhanced by rationally designing polymeric nanoparticle adjuvants. The importance of antigen location for the adjuvanticity of polymeric nanoparticles has not been fully resolved.
Jorge Huete‐Carrasco+6 more
wiley +1 more source
Matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPC. [PDF]
Armstrong AJ+6 more
europepmc +1 more source